专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2380589A3 Improved tuberculosis vaccines 审中-公开
标题翻译：提高结核病疫苗
公开(公告)号：EP2380589A3
公开(公告)日：2012-09-12
申请号：EP11171143.8
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis, M. bovis, M. africanum, M. microti ) . The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

2. 发明授权

EP2163255B1 Tuberculosis vaccines comprising antigens expressed during the latent infection phase 有权
标题翻译：包含在潜伏感染期期间表达的抗原的结核疫苗
公开(公告)号：EP2163255B1
公开(公告)日：2017-08-09
申请号：EP09172905.3
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00

3. 发明公开

EP2402024A1 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 审中-公开
标题翻译： T细胞组库的膨胀为包括通过接种亚优势表位与输送抗原蛋白质片段或肽的鸡尾酒
公开(公告)号：EP2402024A1
公开(公告)日：2012-01-04
申请号：EP11182885.1
申请日：2007-06-26
申请人： Statens Serum Institut
发明人： Aagaard, Claus , Dietrich, Jes , Andersen, Peter
IPC分类号： A61K39/04 , A61K39/02 , A61K39/12 , A61K39/002
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/55511 , A61K2039/5555 , Y02A50/412
摘要： The present invention teaches a way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease by immunizing with pools of overlapping fragments (synthetic peptides e.g. 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The resulting T-cell response to subdominant epitopes is important for protection against chronic diseases that on their own induces a response focused only towards immunodominant epitopes. The present invention requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to multiple of epitopes of vaccine relevance. For chronic disease controlled by humoral immunity the T helper cell response primed by the peptide mix may be boosted by the full size protein for maximum induction of an antibody response as well.
摘要翻译：本发明通过用重叠片段的池进行免疫（合成肽，例如10-30聚体与2-教导诱导的显性和亚优势响应的广泛认识到用于预防或治疗慢性疾病的重要性的任何给定的抗原表位的一种方式在适当的佐剂所需抗原的20个氨基酸重叠）。的T细胞库被起动为不仅包括识别当完整的分子被用于免疫和由慢性感染本身引起的，但诱导了许多的优势表位的更广泛的和平衡的反应以及免疫优势表位。亚优势抗原表位所产生的T细胞反应是针对慢性疾病对她们自己做了保护重要的诱导只注重对免疫表位的响应。本发明要求的优势表位以及它们在人类群体识别的精确定位和身份的先验知识，但扩展T细胞所有组成成分，并通过从数由疫苗接种引发特异性T细胞识别的表位的从而总数免疫抗原表位疫苗相关的多个表位。对于慢性疾病由体液免疫控制由所述肽混合引发T辅助细胞应答可以通过全尺寸为蛋白质的抗体应答的诱导最大被升压为好。

4. 发明公开

EP2380590A3 Improved tuberculosis vaccines 审中-公开
标题翻译：提高结核病疫苗
公开(公告)号：EP2380590A3
公开(公告)日：2012-08-22
申请号：EP11171153.7
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis , M. bovis , M. africanum , M. microti ). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.

5. 发明公开

EP2163255A1 Tuberculosis vaccines comprising antigens expressed during the latent infection phase 有权
标题翻译：在感染的潜伏期含所表达杆菌抗原疫苗
公开(公告)号：EP2163255A1
公开(公告)日：2010-03-17
申请号：EP09172905.3
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis, M bovis, M. africanum, M. microti ). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明在免疫原性组合物，疫苗或用于预防，升压或治疗感染由一个物种的结核配合物（结核分枝杆菌，牛分枝杆菌，非洲分枝，田鼠分枝杆菌）造成的药物组合物有关。免疫原性组合物，疫苗或药物组合物包括融合多肽，其包含来自结核分枝杆菌的一种或多种抗原的饥饿，融合多肽是结核分枝杆菌抗原的单元。此外，本发明是涉及使用一种疫苗，包含在同一时间作为BCG给出的本发明的融合多肽序列或核酸序列的，无论是与BCG混合的或在不同的地点或路线用于制备所述免疫原性组合物分开给药，疫苗或药物组合物。

6. 发明公开

EP2402023A1 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 审中-公开
标题翻译：通过用作为蛋白质片段或肽混合物递送的抗原接种来扩大t细胞库以包括亚优势表位
公开(公告)号：EP2402023A1
公开(公告)日：2012-01-04
申请号：EP11182884.4
申请日：2007-06-26
申请人： Statens Serum Institut
发明人： Aagaard, Claus , Dietrich, Jes , Andersen, Peter
IPC分类号： A61K39/04 , A61K39/02 , A61K39/12 , A61K39/002
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/55511 , A61K2039/5555 , Y02A50/412
摘要： The present invention teaches a way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease by immunizing with pools of overlapping fragments (synthetic peptides e.g. 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The resulting T-cell response to subdominant epitopes is important for protection against chronic diseases that on their own induces a response focused only towards immunodominant epitopes. The present invention requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to multiple of epitopes of vaccine relevance. For chronic disease controlled by humoral immunity the T helper cell response primed by the peptide mix may be boosted by the full size protein for maximum induction of an antibody response as well.
摘要翻译：本发明教导了一种通过用重叠片段库（合成肽例如10-30个菌体，用2-氨基吡啶）免疫来诱导广泛识别对任何给定抗原的表位具有显性和次优势反应的重要性的方法，所述重要性用于预防或治疗慢性疾病。 20个氨基酸重叠）在合适的佐剂中所需的抗原。当完整分子用于免疫接种并由慢性感染自身诱导时，T细胞库不仅包括识别的免疫优势表位，而且还诱导对许多亚优势表位的更广泛和平衡的应答。产生的对亚优势表位的T细胞反应对于防止慢性疾病的保护是重要的，所述慢性疾病本身诱导仅针对免疫显性表位的应答。本发明不需要预先知道亚群表位的精确定位和同一性以及它们在人类群体中的识别，但是扩增了T细胞库，并由此扩大了由接种疫苗引发的特定T细胞识别的表位的总数免疫显性表位与疫苗相关性的多个表位相关联。对于由体液免疫控制的慢性疾病，由肽混合物引发的T辅助细胞应答可以被全长蛋白质加强以最大程度地诱导抗体应答。

7. 发明公开

EP2380590A2 Improved tuberculosis vaccines 审中-公开
标题翻译： Verbesserte Tuberkuloseimpfstoffe
公开(公告)号：EP2380590A2
公开(公告)日：2011-10-26
申请号：EP11171153.7
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis , M. bovis , M. africanum , M. microti ). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明涉及用于预防，增强或治疗由结核分枝杆菌菌种（M.tuberculosis，M.Bovis，M. africanum，M.Microti）引起的感染的免疫原性组合物，疫苗或药物组合物。免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。此外，本发明涉及包含与BCG同时给予的融合多肽序列或本发明的核酸序列的疫苗或与BCG混合或分别在不同部位或途径施用以制备所述免疫原性组合物的疫苗的用途，疫苗或药物组合物。

8. 发明公开

EP2380589A2 Improved tuberculosis vaccines 审中-公开
标题翻译：改进的结核病疫苗
公开(公告)号：EP2380589A2
公开(公告)日：2011-10-26
申请号：EP11171143.8
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis, M. bovis, M. africanum, M. microti ) . The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明涉及用于预防，加强或治疗由结核复合物（结核分枝杆菌，牛分枝杆菌，非洲分枝杆菌，微小分枝杆菌）引起的感染的免疫原性组合物，疫苗或药物组合物。免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。此外，本发明涉及包含与BCG同时给予的本发明的融合多肽序列或核酸序列的疫苗的用途，所述疫苗或者与BCG混合或者分别在不同的位置或者途径中给药以制备所述免疫原性组合物，疫苗或药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式